Ivan D.
- Country
- Bulgaria
- Department
- Medical Oncology Office
Research Overview
- Phase 3 Randomized Study of Gedatolisib Combination Therapy versus Standard Endocrine Therapy in HR‑Positive, HER2‑Negative Advanced Breast Cancer Post‑CDK4/6 Inhibitor
- A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)
- Phase III Randomized Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin vs. Pembrolizumab with Platinum Chemotherapy in Advanced NSCLC Without Genomic Alterations
Data & Insights
Has run more than one trial at 177 of 486 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in the treatment of hormone receptor-positive (ER+) and HER2-negative breast cancer, with particular focus on advanced therapeutic approaches. Their research encompasses both early-stage breast cancer and metastatic breast cancer treatments.
- Extended endocrine therapy optimization
- ESR1 mutation-targeted treatments
- CDK4/6 inhibitor combination strategies
The investigator's work includes evaluating novel therapeutic agents and combination approaches for hormone-dependent breast cancers.
Lung Cancer Expertise
The investigator conducts research in non-small cell lung cancer (NSCLC) treatment, with expertise in both squamous and non-squamous NSCLC. Their work covers various stages of the disease, from locally advanced to metastatic presentations.
- Platinum-based chemotherapy combinations
- Immunotherapy integration
- TROP2-targeted therapies
Their research focuses on developing innovative treatment combinations incorporating immunotherapy and targeted agents for lung cancer patients.
Therapeutic Innovation
The investigator explores novel therapeutic combinations across multiple oncology domains, with particular emphasis on targeted therapy approaches and biomarker-driven treatment strategies.
- Antibody-drug conjugates
- Endocrine resistance mechanisms
- Biomarker validation studies
Their research encompasses the development and evaluation of new therapeutic agents and combination strategies for cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.